INTRODUCTION
Aminoglycosides are widely used in the treatment of gram-negative bacillary infections, including intraabdominal infections. However, these drugs may produce side effects of nephrotoxicity and ototoxicity, particularly when there is volume depletion, shock, advanced age, or renal impairment (23) , risk factors which are common in patients with intra-abdominal infection. The impact of treatment with aminoglycosides on the incidence of nephrotoxicity, as evidenced by an elevation in the serum creatinine concentration, in patients with intra-abdominal infection is shown in Table 1 . There was an appreciably higher incidence of nephrotoxicity with the aminoglycoside-containing regimen in four randomized trials; the effect was statistically significant in at least two studies. Aminoglycoside-induced ototoxicity is potentially more important than nephrotoxicity because it is often not reversible. Cochlear toxicity, as defined by audiometric changes, has been reported in 8 to 10% of patients and was clinically evident in as many as 4% of patients treated with aminoglycosides for various infections (10) . Vestibular toxicity, as detected by electronystagmographic changes, has been found in 5 to 10% of patients and was clinically significant in 1 to 5% of patients (10, 19) .
The development of new beta-lactam antibiotics with potent activity against Bacteroides fragilis and facultative gram-negative bacilli has made it possible to design regimens without aminoglycosides for the treatment of mixed intraabdominal infection. However, these new drugs are costly, and their efficacy as single agents may be questioned by physicians accustomed to using combinations of drugs that include an aminoglycoside.
The purpose of this review is to assess the role of the aminoglycosides in the treatment of intra-abdominal infection. We consider the pathogenesis of this infection, the outcome of comparative studies with and without an aminoglycoside, and the potential utility of aminoglycosides for selected subgroups of patients to ascertain whether these drugs offer an identifiable therapeutic advantage.
(This paper was presented at the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Minn., 29 September to 2 October 1985.)
PATHOGENESIS OF INTRA-ABDOMINAL INFECTION
The microbial species which are commonly present in intra-abdominal infection include anaerobic, facultative, and * Corresponding author. aerobic bacteria, as well as Candida species (Table 2; 11, 25) . The predominant facultative species is Escherichia coli; however, Pseudomonas aeruginosa has been reported in peritoneal cultures of 3 to 15% of patients with peritonitis. The major anaerobic isolates are Bacteroides species, particularly B. fragilis.
Studies in animals have shown that the facultative aerobes are important in producing bacteremia and early mortality in intra-abdominal infection, whereas the anaerobic organisms, especially encapsulated strains of B. fragilis, are instrumental in leading to the formation of abscesses (20, 36) . Implantation of gelatin capsules containing viable E. coli into the abdominal cavity of rats produced an acute bacteremic illness with a mortality rate of 30 to 40% but without abscess formation. In contrast, implantation of capsules containing B. fragilis resulted in abscess formation without death (35, 37) . The implantation of capsules containing both species reproduced the sequence of events seen in clinical intraabdominal infection. Studies in animals suggest that the facultative and anaerobic species operate synergistically to produce tissue destruction in mixed infections (9) .
Further evidence of the role of facultative and anaerobic species emerges from studies of the treatment of experimental infections. Treatment with clindamycin, an agent active against B. fragilis but not E. coli, strikingly reduced the rate of abscess formation but did not influence the lethality of peritonitis, whereas treatment with gentamicin protected against lethality but not against abscess formation (26; Table  3 ). The combination of drugs was effective in reducing both acute mortality and late abscess formation. A number of studies have corroborated these findings in humans (3, 4, 7, 21, 52) . These investigations underline the need to address both the anaerobic component, primarily B. fragilis, and the facultative components, primarily members of the family Enterobacteriaceae, for the optimal treatment of intraabdominal infections.
THEORETICAL CONSIDERATIONS REGARDING EFFICACY
A variety of antibiotics, either singly or in combination, are active in vitro against the predominant species of bacteria found in intra-abdominal infections and might be expected to be effective in treatment. However, there are theoretical reasons why they might not work well clinically. For example, aminoglycosides function poorly in acidic or hypoxic environments (12) , such as would be encountered in abscesses and ischemic tissues. Beta-lactam antibiotics are (25) . Values are the percentage of patients with these isolates identified on culture.
REGIMENS EFFECTIVE FOR INTRA-ABDOMINAL INFECTIONS
Regimens which have been shown in well-designed, prospective, randomized comparative clinical trials to be of equivalent efficacy in the treatment of intra-abdominal infection are shown in Table 4 . For a detailed analysis of these studies, we refer the reader to a recent review (F. P. Tally and J. L. Ho, in J. S. Remington and M. N. Swartz, ed., Current Clinical Topics in Infectious Diseases, vol. 8, in press). The regimens listed in the upper part of Table 4 include an aminoglycoside. However, in one investigation, carbenicillin was given alone to patients with penetrating abdominal trauma with apparent success (34) . Studies with the penicillins were done mainly with ticarcillin; the other congeners are considered acceptable on the basis of their in vitro activity against B. fragilis and limited studies in animals and humans. The regimens shown in the lower part of Table  4 do not contain an aminoglycoside. However, if cefoxitin is used, there are certain circumstances, which are discussed below, in which it is desirable to administer an aminoglycoside concurrently. Two potential regimens for the treatment of intra-abdominal infection are metronidazole plus cefuroxime (39) and clindamycin plus aztreonam. Although present information is limited, future clinical studies may demonstrate the efficacy of these regimens.
COMPARISON OF TRIALS WITH AND WITHOUT AN AMINOGLYCOSIDE
We reviewed publications in peer-reviewed journals of the results of prospective, randomized trials comparing regimens with and without an aminoglycoside in which the dosages of drugs used appeared appropriate to us. We restricted our analysis to studies which had at least 20 Gentamicin alone 4 98
Clindamycin alone 35 5 Gentamicin + clindamycin 7 6 a From Louie et al. (26) . assessable patients in each therapeutic arm, except in one instance (43) in which patients with intra-abdominal infection formed part of a larger study. In most studies, the aminoglycoside was given with clindamycin. The results for cefoxitin, moxalactam, and imipenem are shown in Table 5 .
The criteria for failure of treatment are summarized in the footnotes to Table 5 . Cefoxitin has good activity against B. fragilis and many species of the family Enterobacteriaceae but not against P.
aeruginosa or most strains of Enterobacter spp. In two comparative trials, the results with cefoxitin alone were as good as those with the combination of clindamycin and an aminoglycoside. In the study by Drusano et al. (8) , the patients were seriously ill at the start of treatment because of severe underlying diseases and failure of multiple organs. Five of the twenty-six patients given cefoxitin were also given an aminoglycoside because of the fear that they might harbor cefoxitin-resistant bacteria. Although the outcome with cefoxitin appeared to be better than with the clindamycin-aminoglycoside combination, the differences were not statistically significant in terms of either the cure rate or the failure rate. Nichols and colleagues (32) studied young, previously healthy people who had sustained penetrating intestinal trauma: only 50% of these patients had colonic injuries. As would be expected, the overall outcomes were better than in the study by Drusano and colleagues (8) .
Moxalactam is as active as cefoxitin against B. fragilis but more active than cefoxitin against members of the Enterobacteriaceae, P. aeruginosa, and Enterobacter species. Schentag and colleagues (44) almost identical between the two regimens. The incidence of superinfection was substantial (21 to 33%). The study by Tally and colleagues (50) compared the efficacy of moxalactam with that of cefoxitin, the latter sometimes given with an aminoglycoside, in a varied group of patients, not all of whom had intra-abdominal infections. Because only 13 patients in the cefoxitin-treated group were given the aminoglycoside, this trial does not fully meet our purposes. Nevertheless, the outcome of the two regimens was again similar in the two study trials. Imipenem has potent activity against most bacterial species likely to be encountered in intra-abdominal infection, including B. fragilis, most members of the Enterobacteriaceae (including Enterobacter spp.), P. aeruginosa, and Streptococcus faecalis (2) . The efficacy of imipenem has been compared with that of the combination of clindamycin and gentamicin in two trials. The first was part of a larger study of various kinds of infections; the overall results showed a statistically significant benefit for imipenem over the combination of clindamycin and gentamicin (43) . The subset of patients with intra-abdominal infection shown in Table 5 was small. Although the results suggested better efficacy of imipenem than of the combination, the differences were not significant. In the second trial, the differences between the regimens were modest and, again, not statistically significant (48) . The failure rate with clindamycin and gentamicin in the second study may have been skewed upward by an unusually high incidence of gentamicinresistant, gram-negative bacilli in the institution during the study period. In both trials with imipenem, about 10% of patients in each treatment group developed superinfections. A third study, by Guerra and colleagues (13) , also yielded a somewhat better outcome with imipenem than with the combination of clindamycin and gentamicin, but it involved few patients with intra-abdominal infection. The suggestion of a better outcome with imipenem than with the aminoglycoside-containing regimen in these studies is interesting but needs to be confirmed in larger trials. Although imipenem has excellent activity against P. aeruginosa, some strains have become resistant to the drug during clinical trials involving other kinds of infections (27, 40) .
Cefoperazone has good activity and cefamandole has moderate activity against facultative gram-negative bacilli, but these agents have relatively poor activity against B. fragilis in vitro (49) . Therefore, these drugs would not be expected to produce optimal results as single agents for the treatment of intra-abdominal infection. In a study of patients with perforated appendix or periappendiceal abscess, Berne et al. (3) found the failure rate to be significantly higher after treatment with cefamandole (28%) or cefoperazone (16%) than after treatment with the combination of clindamycin and gentamicin (0%; P < 0.05). Lau et al. (22) also showed a failure rate with cefoperazone (20%) significantly higher than that with moxalactam (8%) in patients with perforated or gangrenous appendicitis. In a further analysis of data from the first study, the likelihood of failure was found to be greatest in patients from whom B. fragilis isolated from the abdominal cavity at surgery was resistant to the antibiotics used (18) . A previous report likewise suggested that failures of treatment of intra-abdominal infection with moxalactam were predicted by the finding of moxalactam-resistant anaerobic bacteria in the initial cultures (30) . These studies again underline the importance of using a regimen with good activity against B. fragilis in the treatment of intraabdominal infection.
Many of the newer cephalosporins have potent activity against members of the Enterobacteriaceae but not against B. fragilis; this deficiency could be corrected by giving the cephalosporin in combination with a drug such as metroni- b Based on number of isolates rather than patients with these isolates. Calculation was made as if each isolate were from a different patient. Fifty of seventy-four patients had intra-abdominal infection.
dazole. In one study, the combination of metronidazole and cefuroxime was compared with the combination of metronidazole and gentamicin in 42 patients with perforated appendicitis (39) . The outcome of the two regimens was similar in terms of length of hospital stay and the percentage of patients with postoperative fever.
It can be concluded on the basis of these trials that there are no demonstrable differences in efficacy or in the incidence of superinfections between regimens containing or lacking an aminoglycoside when used for the treatment of intra-abdominal infection. However, differences in efficacy rates of as much as 10% might easily be missed because of the sizes of the groups studied. For example, if we assume an 80% response rate in the control group and a 90% response rate in the group receiving putatively better treatment, there would have to be 120 patients in each limb of the study to achieve significance at the 95% level (55) . OUTCOME OF INFECTIONS WITH P. AERUGINOSA OR ENTEROBACTER SPP. The patients most likely to benefit from the inclusion of an aminoglycoside in the treatment regimen for intra-abdominal infections presumably are the subset from whom P. aeruginosa or an Enterobacter spp. was isolated from the initial culture. In a study of patients with a perforated or gangrenous appendix, Heseltine et al. (18) examined the correlation between the susceptibility or resistance of P. aeruginosa strains isolated from the initial culture and the outcome of treatment with various regimens ( Table 6 ). In that study, 30% of patients had peritoneal cultures which were positive for P. aeruginosa. Treatment with cefamandole, to which all initial isolates of P. aeruginosa were resistant, or with cefoperazone, to which all initial isolates were susceptible, resulted in cure of about half of the patients. In contrast, treatment with gentamicin, to which most strains were susceptible, was almost uniformly successful. This suggests that patients from whom P. aeruginosa is cultured from the initial infection may benefit from treatment with an aminoglycoside. Of course, other beta-lactam antibiotics are more pdtent than cefoperazone against P. aeruginosa and Enterobacter species, and the results with such agents might be more impressive. However, there continues to be concern because of the recognized tendency of P. aeruginosa and Enterobacter spp. to become resistant to beta-lactam antibiotics during treatment (14, 41) .
To determine the frequency of isolation of these relatively resistant species, we reviewed the studies summarized in In the study by Nichols and colleagues (32) , the rate of isolation of Kebsiella, Enterobacter, and Serratia species from sites of infectious complications in patients treated with an aminoglycoside was lower than that in patients treated with cefoxitin (Table 8 ). In contrast, Schentag and colleagues (44) with an aminoglycoside-containing regimen. Thus, the inclusion of an aminoglycoside did not enhance the efficacy of treatment in these patients. However, all patients in whom there was failure of treatment with cefoxitin alone harbored cefoxitin-resistant organisms at the site of infectious complications, whereas none of the patients in whom there was failure of treatment with an aminoglycoside harbored such organisms. This suggests that the use of an aminoglycoside in patients with infection containing beta-lactam-resistant organisms does not affect the clinical outcome but may influence the composition of the flora at the site of infectious complications.
CONCLUSIONS
On the basis of our review of the literature, we find no evidence of a difference in efficacy for the treatment of intra-abdominal infection between regimens which contain and do not contain an aminoglycoside. This holds true even for studies of seriously ill patients and patients whose initial cultures contain beta-lactam-resistant bacteria. There was also no evidence of a difference in the incidence of superinfections between regimens with and without an arpinoglycoside. However, the studies were not large enough to determine whether the subgroup of patients (5 to 18%) whose initial cultures yielded P. aeruginosa or Enterobacter spp. might have had a particular benefit from the aminoglycosidecontaining regimen. Such a benefit was suggested by one study (18) .
The inclusion of an aminoglycoside in the regimen appeared in certain studies to influence the composition (32) and susceptibility patterns (8) of the flora isolated from infectious complications after treatment for intra-abdominal infection. Thus, patients from whom the initial cultures yielded beta-lactam-resistant bacteria tended to have these organisms present in the infectious complications after treatment with a beta-lactam drug but not after treatment with an aminoglycoside-containing regimen (8) . However, even in these patients, there was no apparent difference in clinical outcome whether or not an aminoglycoside was given.
Leaving aside considerations of cost and of the potential toxicities of the nonaminoglycoside drugs which may be of particular importance in certain patients (1, 42) , the decision to include an aminoglycoside in the antibiotic regimen for the initial empiric treatment of intra-abdominal infection remains a difficult one. It may be particularly justifiable to include an aminoglycoside when there is substantial risk that P. aeruginosa or Enterobacter spp. are present at the site of infection as, for example, in patients who sustain their infections in hospitals or nursing homes and in patients who have recently received broad-spectrum antibiotics (38) or immunosuppressive treatments. In any event, if the cultures fail to yield beta-lactam-resistant bacteria, there appears to be no benefit to continuing the administration of an aminoglycoside antibiotic.
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